GW Pharmaceuticals announced that its pipeline compound GWP42006 failed to meet its primary endpoint in a Phase IIa proof of concept study for patients with focal seizures. Source: BioSpace

Shares of Regeneron are down following reports of increased observations of known side effects from blockbuster drug Eylea were reported by providing doctors. Source: BioSpace

New York-based Kallyope Inc. has secured an additional $66 million in Series B funding that it will use to continue its work harnessing the communicative pathways between the digestive tract…

AbbVie and Neurocrine Biosciences’ Phase III ELARIS UF-1 clinical trial of elagolix for uterine fibroids hit its primary endpoint. Source: BioSpace

Johnson & Johnson is hoping its $100 million deal with Theravance will serve as a replacement for Remicade which lost patent protection. Source: BioSpace

Here is a look at the life science companies viewed as the most innovative in the world. Source: BioSpace

The U.S. Food and Drug Administration (FDA) granted San Diego-based Evofem Biosciences Fast Track designation for Amphora vaginal gel to prevent urogenital chlamydia infection in women. Source: BioSpace

A new chief executive officer and a fresh infusion of $50 million in Series C funding has given Bay Area ORIC Pharmaceuticals a shot in the arm as it continues…

Life sciences giant Johnson & Johnson may be shopping around its sterilization products division. Source: BioSpace

Nevada-based PDL BioPharma, Inc. said it will no longer pursue a proposed acquisition of Neos Therapeutics. Source: BioSpace